Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER TEENS oral semaglutide in adolescents with type 2 diabetes
NL-OMON58781Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing oral semaglutide with placebo (2 arms). Primary endpoint: Change in HbA1c at week 26. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON58781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58781.